Tango Therapeutics (NASDAQ:TNGX) Stock Price Expected to Rise, Wedbush Analyst Says

Tango Therapeutics (NASDAQ:TNGX) had its price target raised by equities researchers at Wedbush from $15.00 to $19.00 in a research note issued on Friday,Benzinga reports. The brokerage currently has an “outperform” rating on the stock. Wedbush’s price objective points to a potential upside of 12.09% from the company’s previous close.

Several other research analysts also recently weighed in on the company. Piper Sandler increased their target price on Tango Therapeutics from $11.00 to $14.00 and gave the company an “overweight” rating in a research report on Friday, January 16th. Guggenheim boosted their price target on shares of Tango Therapeutics from $18.00 to $20.00 and gave the stock a “buy” rating in a report on Friday. Weiss Ratings restated a “sell (e+)” rating on shares of Tango Therapeutics in a research report on Wednesday, January 21st. B. Riley Financial increased their price objective on shares of Tango Therapeutics from $8.00 to $14.00 and gave the company a “buy” rating in a report on Tuesday, November 18th. Finally, Jefferies Financial Group reiterated a “buy” rating and issued a $18.00 target price on shares of Tango Therapeutics in a research report on Thursday. Nine analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Tango Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $18.25.

Tango Therapeutics Stock Up 0.7%

Shares of Tango Therapeutics stock opened at $16.95 on Friday. The firm has a market cap of $2.28 billion, a PE ratio of -19.48 and a beta of 1.76. Tango Therapeutics has a twelve month low of $1.03 and a twelve month high of $17.63. The business has a 50-day moving average price of $11.86 and a 200 day moving average price of $9.46.

Tango Therapeutics (NASDAQ:TNGX) last issued its quarterly earnings results on Thursday, March 5th. The company reported ($0.29) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.31) by $0.02. Tango Therapeutics had a negative return on equity of 66.01% and a negative net margin of 151.15%. On average, sell-side analysts expect that Tango Therapeutics will post -1.19 EPS for the current year.

Insider Buying and Selling

In other Tango Therapeutics news, insider Adam Crystal sold 54,345 shares of the firm’s stock in a transaction on Wednesday, February 25th. The stock was sold at an average price of $12.77, for a total value of $693,985.65. Following the transaction, the insider owned 132,873 shares in the company, valued at approximately $1,696,788.21. This trade represents a 29.03% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Barbara Weber sold 30,519 shares of Tango Therapeutics stock in a transaction on Tuesday, February 3rd. The stock was sold at an average price of $12.26, for a total transaction of $374,162.94. Following the sale, the director directly owned 1,629,254 shares in the company, valued at approximately $19,974,654.04. This trade represents a 1.84% decrease in their position. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 113,633 shares of company stock worth $1,420,857. 7.50% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Tango Therapeutics

Hedge funds have recently modified their holdings of the business. Global Retirement Partners LLC purchased a new position in shares of Tango Therapeutics in the fourth quarter worth about $35,000. Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in Tango Therapeutics by 148,800.0% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 4,467 shares of the company’s stock valued at $40,000 after acquiring an additional 4,464 shares during the last quarter. ANTIPODES PARTNERS Ltd purchased a new position in Tango Therapeutics in the 4th quarter worth approximately $40,000. CWM LLC lifted its stake in Tango Therapeutics by 182.2% in the 2nd quarter. CWM LLC now owns 4,905 shares of the company’s stock worth $25,000 after purchasing an additional 3,167 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. boosted its holdings in shares of Tango Therapeutics by 52.2% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 6,544 shares of the company’s stock worth $58,000 after purchasing an additional 2,243 shares during the last quarter. 78.99% of the stock is currently owned by institutional investors and hedge funds.

Tango Therapeutics News Summary

Here are the key news stories impacting Tango Therapeutics this week:

• Positive Sentiment: Clinical collaboration with Erasca to test ERAS‑0015/vopimetostat in MTAP‑deleted, RAS‑mutant cancers expands Tango’s clinical footprint and creates near‑term partnership newsflow that likely drove buying interest and record highs. TNGX Stock Hits Record High on Inking Collaboration Deal With ERAS
• Positive Sentiment: HC Wainwright sharply raised its price target to $27 (buy), a large explicit upside that can boost sentiment and buy‑side conviction. HC Wainwright price target raise
• Positive Sentiment: Guggenheim raised its target to $20 and reiterated a buy rating, adding to analyst momentum and supporting the share‑price lift. Guggenheim price target raise
• Positive Sentiment: Wedbush raised its target to $19 with an “outperform” rating, another vote of confidence from sell‑side analysts that can attract new buyers. Wedbush price target raise
• Positive Sentiment: An investment firm added ~1.1M shares (~$9.5M), increasing its reported position materially — institutional buying that signals conviction and can underpin the rally. Investment Firm Bets Big on TNGX Stock
• Neutral Sentiment: Quarterly results beat EPS estimates by $0.02 (reported -$0.29 vs. -$0.31) — a modest positive but company remains unprofitable with negative margins and ROE, so financials are unlikely to change valuation narrative immediately. Tango Therapeutics press release
• Negative Sentiment: A Seeking Alpha piece warns against buying into the rally despite PRMT5 promise, highlighting clinical, competitive and valuation risks that could limit upside or prompt pullbacks if trial data or execution falter. Tango Therapeutics: I’m Not Buying Into Latest Rally

About Tango Therapeutics

Tango Therapeutics is a clinical-stage biotechnology company dedicated to developing precision medicines that exploit genetic vulnerabilities in cancer cells. Leveraging a proprietary synthetic lethality platform, the company identifies and targets tumor-specific dependencies in DNA damage response and related pathways. By focusing on tumor cell collateral sensitivities, Tango aims to bring differentiated small-molecule therapies to patients with genetic alterations that confer increased susceptibility to targeted inhibition.

The company’s lead pipeline comprises several early-stage programs, including inhibitors designed to selectively disable DNA repair proteins in tumor cells while sparing normal tissues.